NATIONAL INSTITUTES OF HEALTH
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
A Randomized Phase III Trial of Hyperthermic Isolated Limb Perfusion With Melphalan, Tumor Necrosis Factor, and Interferon-Gamma in Patients With Locally Advanced Extremity Melanoma
Phase 3
Completed
- Conditions
- Melanoma
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 122
- Registration Number
- NCT00001296
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Feasibility Study of Interleukin 1-Alpha With Ifosfamide, CBDCA, and Etoposide With Autologous Bone Marrow Transplant in Metastatic Carcinoma and Lymphoma
Phase 1
Completed
- Conditions
- LymphomaNeoplasm MetastasisBreast NeoplasmsTesticular Neoplasms
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 85
- Registration Number
- NCT00001270
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
A Phase I Study of Isolated Hepatic Portal and Arterial Perfusion (IHP) With Escalating Dose Melphalan for Primary or Metastatic Unresectable Cancers of the Liver
Phase 1
Completed
- Conditions
- Neoplasm MetastasisLiver Neoplasms
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT00001587
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Studies of the Immune Response in Normal Subjects and Patients With Disorders of the Immune System
Completed
- Conditions
- NeoplasmsImmunologic Deficiency Syndromes
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00001158
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Vinorelbine and XR9576 to Treat Cancer
Phase 1
Completed
- Conditions
- CancerLung CancerOvarian CancerBreast Cancer
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT00001944
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
A Phase I Study of Weekly Gemcitabine in Combination With Infusional Fluorodeoxyuridine and Oral Calcium Leucovorin in Adult Cancer Patients
Phase 1
Completed
- Conditions
- Neoplasms
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 60
- Registration Number
- NCT00001449
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Immunization of HLA-A201 Patients With Metastatic Melanoma Using a Combination of Immunodominant Peptides From Three Melanoma Antigens, MART-1, GP100 and Tyrosinase
Phase 2
Completed
- Conditions
- Neoplasm MetastasisMelanoma
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 114
- Registration Number
- NCT00001685
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Phase I Study of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Escalating Dose I.P. Platinum for Gastrointestinal Peritoneal Carcinomatosis
Phase 1
Completed
- Conditions
- Peritoneal NeoplasmsStomach Neoplasms
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 50
- Registration Number
- NCT00001332
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
A Pilot Study of Non-Hodgkin's Lymphoma: Chemotherapy and Blood Levels of Organochlorines
Completed
- Conditions
- HIV InfectionsLymphoma, AIDS-RelatedLymphoma, Non-Hodgkin
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 20
- Registration Number
- NCT00001571
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Determination of HIV-1 Production by the Prostate
Completed
- Conditions
- HIV Infections
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 35
- Registration Number
- NCT00001584
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
© Copyright 2025. All Rights Reserved by MedPath